Capital/Financing Update • Dec 18, 2014
Capital/Financing Update
Open in ViewerOpens in native device viewer
BAGNEUX, France, December 18, 2014 ‐ DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ‐ Nasdaq Stock Market: DBVT), a clinical‐stage specialty biopharmaceutical company, announced today an additional contribution on December 17th, 2014 of 600,000 euros to the liquidity agreement held by Natixis in accordance with the Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the Autorité des Marchés Financiers.
During the half‐year report as of June 30th, 2014, the following elements were in the liquidity account:
For information, the following elements appeared on the liquidity account at the time of the implementation of the liquidity contract:
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide‐patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one‐half of one ordinary share) (Ticker: DBVT).
For more information on DBV Technologies, please visit our website: www.dbv‐technologies.com
David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 david.schilansky@dbv‐technologies.com
VP Finance, US Investor Relations & Strategy Tel. : +1 917‐346‐3447 susanna.mesa@dbv‐technologies.com
Director, Corporate Communication & Business Development Tel. : +33(0)1 55 42 78 72 nathalie.donne@dbv‐technologies.com
U.S. Investor Relations The Trout Group Tel. : +1 646‐378‐2926 [email protected] Rooney & Associates Media Relations Marion Janic Tel. : +1‐212‐223‐4017 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.